Part of meridian hospital co. plc
Clinical Trials
8
5 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2005
Active, not recruiting
5
62.5%
Completed
2
25.0%
Unknown
1
12.5%
No approval data available
- A 43-year-old bowel cancer patient became one of the first people globally to receive a personalized mRNA cancer vaccine designed to prevent cancer recurrence. - The vaccine uses genetic analysis of tumor samples to identify abnormal proteins and employs mRNA technology similar to COVID vaccines to train the immune system. - Early results from similar approaches in advanced skin cancers show promise, with researchers expecting clearer efficacy data within two to five years. - The patient received nearly 20 doses over a year, with initial side effects including fever and shaking that diminished over time.
- Queen Elizabeth Hospital in King's Lynn has become the UK's leading recruiter in a global AstraZeneca-sponsored heart failure clinical trial, successfully enrolling five patients. - The trial provides patients access to cutting-edge investigational treatments, marking a significant milestone for the smaller hospital competing against larger medical centers. - Heart failure affects approximately 920,000 people in the UK with 200,000 new diagnoses annually, and these figures are expected to nearly double by 2040 according to NHS England.
- Yaqrit has received a £2.2 million ($2.85 million) grant from the UK's National Institute for Health and Care Research to fund pivotal trials of its DIALIVE liver support device across 13 UK centers. - The DIALIVE device treats Acute-on-Chronic Liver Failure (ACLF) by removing disease-causing toxins from blood and exchanging dysfunctional albumin, showing twice the resolution rate compared to standard care in previous studies. - The randomized trial will enroll approximately 70 high-risk ACLF grade 2-3 patients, with results expected in Q1 2027, potentially offering new hope for a condition that carries 40-80% mortality within 28 days.
